共 50 条
Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review
被引:39
|作者:
Buoli, Massimiliano
[1
]
Serati, Marta
[1
]
Altamura, A. Carlo
[1
]
机构:
[1] Univ Milan, Dept Psychiat, Fdn IRCCS Ca Granda, Osped Maggiore Policlin, I-20122 Milan, Italy
关键词:
Bipolar Disorder;
Mood stabilizers;
Antipsychotics;
Combined treatment;
NEUROLEPTIC MALIGNANT SYNDROME;
PLACEBO-CONTROLLED TRIAL;
DOUBLE-BLIND;
I-DISORDER;
MAINTENANCE TREATMENT;
RELAPSE PREVENTION;
ADJUNCTIVE ARIPIPRAZOLE;
FOLLOW-UP;
LITHIUM;
RISPERIDONE;
D O I:
10.1016/j.jad.2013.08.024
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Background: Bipolar Disorder (BD) long-term treatment is aimed to prevent relapses associated with worsening cognitive impairment and chronicity. Available mood stabilizers, including lithium, fail to prevent relapses in about 40% of bipolar patients. Purpose of the present paper is to review the available data about the efficacy and tolerability of mood stabilizer plus antipsychotic combined treatments. Method: A research in the main database sources has been conducted to obtain an overview about the efficacy and tolerability of the combination of a mood stabilizer plus an antipsychotic in the long-term treatment of BD. Papers with different methodologies but having relapse prevention as main outcome have been included. Results: Despite the heterogeneity of studies in terms of methodology, almost all papers reported a major efficacy of combined treatments respect to mood stabilizer mono-therapies but lower tolerability. The antipsychotic that presents more evidence of efficacy in combination with mood stabilizers is quetiapine. Discussion: Combined treatments can be a valid option to improve relapse prevention in BD. However, the higher risk for side effects has to be taken into account and specific combinations should be preferred according to patients' medical comorbidity. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:12 / 18
页数:7
相关论文